Cyclic AMP comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-05-13. Numbers and descriptions here follow the published literature rather than marketing material.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Whether the drug improves hard clinical outcomes is not settled. No completed trial has shown a reduction in heart attacks or strokes among treated patients, although a dedicated cardiovascular outcomes study has been discussed in the literature. Investigators have also examined hepatic fat in people with HIV and fatty liver disease, cognitive measures in small cohorts, and changes in bone density. Regulatory labeling emphasizes monitoring of insulin-like growth factor 1 because supraphysiologic levels raise questions about tissue growth, and the clinical significance of that signal remains an open question rather than a demonstrated harm.
Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue peptide | GHRH analog backbone |
| Approximate molecular mass | 5136 Da | Varies with counterion and hydration state |
| N-terminal group | trans-3-hexenoyl | Increases resistance to dipeptidyl peptidase IV |
| Primary receptor | GHRH receptor (GHRHR) | Class B G protein-coupled receptor on somatotrophs |
| Principal mediator | IGF-1 | Rises indirectly after growth hormone release |
作用位置在垂体前叶。tesamorelin 与 GHRH 受体结合后激活腺苷酸环化酶，升高细胞内 cAMP，再经蛋白激酶 A 通路促进生长激素的合成与释放。由于它作用于内源调控节点，生长激素仍以脉冲方式分泌，而不是被持续抬升到固定水平。生长激素随后在肝脏等组织诱导胰岛素样生长因子 1 产生，构成完整的生长激素轴响应。
研究背景集中在特定人群的体成分改变，尤其是与脂肪分布异常相关的内脏脂肪堆积。不同地区对它的监管状态与获批适应症并不一致，部分市场仅限特定诊断人群使用。在一般人群中的长期效应、与其他激素的相互作用以及停药后的维持情况仍属开放问题，现有数据不足以给出普遍结论。
tesamorelin 是一种人工合成的四十四肽，序列与内源性生长激素释放激素（GHRH）的 1-44 片段一致，区别在于 N 端加接了一个反式-3-己烯酰基。该修饰抑制二肽基肽酶 IV 的快速切割，从而延长分子在循环中的存留时间。作为肽类分子，它难以经胃肠道吸收，文献中讨论的均是注射途径。分类上通常把它归为 GHRH 类似物，以区别于生长激素本身。
Research supply is often accompanied by a certificate of analysis listing chromatographic purity, mass confirmation, and storage conditions. Laboratories compare that document with an independent test when material is intended for bench work, since certificates describe a batch rather than an individual vial. Published studies usually state the source and purity of the peptide because small differences in purity can shift measured activity. Full analytical validation is rarely reported, which leaves batch-to-batch comparability an open question.
The peptide is supplied as a lyophilized powder in single-use vials and is normally kept refrigerated between two and eight degrees Celsius, protected from light. Once dissolved, the solution is handled carefully because peptide bonds and the acyl modification can degrade under warm or alkaline conditions. Vials are inspected for cracks, and the powder is checked for color and uniformity before handling. Temperature excursions during shipping are a frequent reason for quality questions.
监管记录显示，特沙莫瑞林于 2010 年在美国首次获得批准，用于人类免疫缺陷病毒感染相关的脂肪营养不良患者。批准依据来自降低内脏脂肪的临床试验，而非体重或瘦体重的普遍改善。后续出现了不同制剂版本，但其核心适应症保持一致。关于长期心血管结局和死亡率影响，现有证据仍不充分。
在临床研究之外，特沙莫瑞林常被讨论为生长激素分泌促进剂，但这一说法需要限定。它并不等同于生长激素本身，也不属于普通减重药物。部分研究关注其减少腹部脂肪和改善脂质谱的潜力，另一些研究则关注胰岛素抵抗和 IGF-1 升高等信号。这些效应的临床意义仍在评估中，尚未形成统一结论。
Published work tends to frame tesamorelin as a tool for studying the GHRH axis and as a compound with measurable effects on body composition. Reports often describe visceral adipose tissue as an endpoint, assessed by imaging rather than by inference. Analytical sections commonly describe liquid chromatography with tandem mass spectrometry to confirm identity and purity, because immunoassays may cross-react with related fragments. Where results diverge between studies, differences in assay choice, sampling timing, and population are frequent explanations offered. Whether effects persist after treatment stops remains an open question.
Tesamorelin binds the growth hormone–releasing hormone receptor on pituitary somatotroph cells. The receptor signals through the Gs protein, raising intracellular cAMP and activating protein kinase A. That cascade triggers release of stored growth hormone in pulses rather than a steady stream. Because the drug acts at the receptor that normally controls this process, its effect depends on the body's own signaling architecture rather than on a synthetic pathway. The resulting hormone profile reflects the timing of each pulse, not only its size.
==== Gene Microarrays ==== Traditionally DNA microarrays use complementary DNA or oligonucleotide probes to analyze messenger RNA (mRNA) from genes of interest. Extracted total RNA serves as a template for complementary DNA (cDNA) that is tagged with fluorescent probes before being allowed to hybridize to the microarray for visualization. For proteases, specific probes for protease genes and their inhibitors have been developed to view expression patterns on the mRNA transcript level. The two platforms currently available for this purpose come from corporate and academic sources. Affymetrix's Hu/Mu ProtIn Microarray uses 516 and 456 probe sets to evaluate human and murine proteases, inhibitors, and interactors respectively. CLIP-CHIP™, developed by the Overall Lab, is a complete protease and inhibitor DNA microarray for all 1561 human and murine proteases, non-proteolytic homologues, and their inhibitors. Both of these tools allow comparison of expression patterns between normal and diseased samples and tissues. Unfortunately, as transcript levels often fail to reflect protein expression levels, gene microarrays are limited in representing protein in samples. In addition, proteases recruited from remote sources like nearby tissues are ignored by these DNA based arrays, reiterating the need for protein based methods to confirm the presence and activity of functional enzymes when transcriptome analysis is performed.
=== MSEIRS model === An MSEIRS model is similar to the MSEIR, but the immunity in the R class would be temporary, so that individuals would regain their susceptibility when the temporary immunity ended.
9 May – Protesters gather in several centres including Auckland, Dunedin, Christchurch, Rolleston and New Plymouth to protest against the Government's new Pay Equality Amendment Act 2025. 10 May – Protest against the Government's new Pay Equity legislation are held in Nelson and Ōtaki. 11 May – The Christchurch City Council extends the state of emergency in Banks Peninsula in response to a landslip in Akaroa. 12 May: Mayor of Christchurch Phil Mauger lifts Banks Peninsula's local state of emergency. Deputy Police Commissioner Jevon McSkimming resigns following a four-month Police and Independent Police Conduct Authority investigation into serious misconduct including pornography being found on a Police-issued device. 14 May – A parliamentary committee approves a motion against Te Pāti Māori MPs Hana-Rāwhiti Maipi-Clarke, Rawiri Waititi and Debbie Ngarewa-Packer censuring and banning them from entering the parliamentary buildings for up to 21 days for their performance of a haka against their opponents during a parliamentary debate over the Treaty Principles Bill. 15 May – The New Zealand Government apologises to the Māori iwi Ngāti Ranginui for land confiscations and a scorched earth campaign during the New Zealand Wars. Parliament also passes legislation compensating the tribe NZ$38 million and designating 15 sites of significances to the tribe. 16 May: The USS Blue Ridge visited Wellington to reaffirm bilateral relations with New Zealand. This marked the first visit to Wellington by a US warship since 2021.
Long before the born secret issues associated with the restricted data provisions of the US Atomic Energy Act of 1946, the US Invention Secrecy Act of 1951, and the US Patent and Trademark Law Amendments Act of 1980 and/or the increasing concerns with respect to the on-going biopiracy of natural products, and in the early 20th-century atmosphere of cultural change — not only in the proliferation of vocational universities, rather than research universities, but also in the gradual move from the disciplinary concentration on "pure science" and, perhaps, aspects of "applied science", to that of fostering "industrial science" in both primary and secondary industries — the ethical question of whether or not those universities devoted to "pure science" (viz., the discovery/creation, distillation, refinement, diffusion, and the free dissemination of knowledge for the benefit of the public) should have any interest in "applied science", and further, whether they should have any commercial interest in the products of their research and, in particular, whether they should seek patents for their discoveries. In his 1926 Presidential address to the Society of American Bacteriologists (HZ.1), Hans Zinsser spoke against "the growing tendency on the part of medical scientific workers, and bacteriologists especially, to patent discoveries of practical therapeutic and public health value" (p.157).
== Public debate and criticisms == The plan to build the integrated resorts was subject to considerable debate among Singaporeans even until 2014. Several groups, especially those belonging to religious communities as well as social workers, openly expressed their disapproval of the casinos. Concerns were raised about the negative social impact of casino gambling, citing worries that the casinos could encourage more gambling and increase the risk of compulsive gambling. Activist groups argued that a casino could also lead to undesirable activities often associated with gambling, including money laundering, loan sharks or even organized crime. Lee acknowledged the downsides of having integrated resorts and the concerns expressed by the public. He promised that there would be safeguards to limit the social impact of casino gambling. He stated there would be restrictions on the admission of local people into the casinos. Lee announced a steep entrance fee of S$100 per entry or S$2,000 per year (increased to $150 per entry or $3,000 per year on 4 April 2019) and a system of exclusions for all Singaporeans. In addition, the casinos would not be allowed to extend credit to the local population who are not premium players. Premium players are players who opened a deposit account with the casino and has a credit balance of at least SGD $100,000. The six-month consultative period gave the opportunity for many sections of the population to voice their opposition to the casinos, including a petition hat attracted tens of thousands of signatures.
Sources: en.wikipedia.org
Pakistan was ranked 99th in the Global Innovation Index by 2025. The 1960s marked the rise of Pakistan's space program, led by SUPARCO, yielding advancements in rocketry, electronics, and aeronomy. Notably, Pakistan launched its first rocket into space, pioneering South Asia's space exploration. In 1990, it successfully launched its first satellite, becoming the first Muslim nation and second in South Asia to achieve this milestone.
==== Suicide ==== In studies in Sweden, flunitrazepam was the second most common drug used in suicides, being found in about 16% of cases. In a retrospective Swedish study of 1,587 deaths, in 159 cases benzodiazepines were found. In suicides when benzodiazepines were implicated, the benzodiazepines flunitrazepam and nitrazepam occurred in significantly higher concentrations compared to natural deaths. Of the 159 deaths where any benzodiazepines were found, 4 deaths were caused by benzodiazepines alone (in the other 155 cases, benzodiazepines were combined with something else). One conclusion of the study was that flunitrazepam and nitrazepam might be more toxic than other benzodiazepines available in the Swedish market.
Teicoplanin is a glycopeptide antibiotic with a spectrum of activity similar to vancomycin. Its mechanism of action is to inhibit bacterial cell wall peptidoglycan synthesis. It is used in the prophylaxis and treatment of serious infections caused by Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus and Enterococcus faecalis. Teicoplanin is widely available in many European, Asian, and South American countries, however it is not currently approved by the US Food and Drug Administration and is not commercially available in the United States. Teicoplanin is marketed by Sanofi-Aventis under the trade name Targocid. Other trade names include Ticocin marketed by Cipla(India). Its strength is considered to be due to the length of the hydrocarbon chain.
== History == UK-5099 (JXL001), the earlier MPC inhibitor from which suvomipic was derived, was first described in the scientific literature by 1975. Suvomipic is under development by Pelage Pharmaceuticals. In 2025, it was reported that lab work on the drug had been ongoing for almost a decade. It originated at the University of California, Los Angeles (UCLA), with Pelage Pharmaceuticals being founded and spun out of UCLA in 2018 by three scientists at the university. These academics included Bill Lowry, Heather Christofk, and Michael Jung. The chief medical officer (CMO) of the company is Qing Yu Christina Weng. Pelage Pharmaceuticals was named after the French word for "coat of fur" and "PP405" was named after the company and the 405 freeway that goes through Los Angeles. The first human clinical trials of suvomipic started in 2023 in Orange County.
Sources: en.wikipedia.org
Red Acid fuchsin, xylidine ponceau, chromotrope 2R, Biebrich scarlet, ponceau 6R, phloxine Blue and green Light green SF yellowish, Fast Green FCF, methyl blue, water blue Yellow Picric acid, orange G, Martius yellow, tartrazine, milling yellow
Technetium (43Tc) is one of the two elements with Z < 83 that have no stable isotopes; the other such element is promethium. It is primarily artificial, with only trace quantities existing in nature produced by spontaneous fission (there are an estimated 2.5×10−13 grams of 99Tc per gram of pitchblende) or neutron capture by molybdenum. The element was first obtained in 1936 from bombarded molybdenum, the first artificial element to be produced. The most stable radioisotopes are 97Tc (half-life of 4.21 million years), 98Tc (half-life: 4.2 million years), and 99Tc (half-life: 211,100 years). Given that their stated uncertainties are 16 and 30 times their difference, the half-lives of 97Tc and 98Tc are statistically indistinguishable. Thirty-three other radioisotopes have been characterized with atomic masses ranging from 85Tc to 120Tc. Those with half-lives more than an hour have masses 93 to 96. Technetium also has numerous meta states. 97mTc is the most stable, with a half-life of 91.1 days (0.097 MeV), followed by 95mTc (half-life: 62.0 days, 0.039 MeV) and 99mTc (half-life: 6.01 hours, 0.143 MeV). 99mTc emits only gamma rays while decaying to 99Tc. For isotopes lighter than 98Tc, the primary decay mode is electron capture to isotopes of molybdenum. For the heavier isotopes, the primary mode is beta emission to isotopes of ruthenium, with the exception that 98Tc and 100Tc can decay both by beta emission and electron capture. Technetium-99m is the technetium isotope employed in the nuclear medicine industry.
However, several academic researchers became concerned that AI was no longer pursuing its original goal of creating versatile, fully intelligent machines. Beginning around 2002, they founded the subfield of artificial general intelligence (or "AGI"), which had several well-funded institutions by the 2010s. Deep learning began to dominate industry benchmarks in 2012 and was adopted throughout the field. For many specific tasks, other methods were abandoned. Deep learning's success was based on both hardware improvements (faster computers, graphics processing units, cloud computing) and access to large amounts of data (including curated datasets, such as ImageNet). Neural-network approaches also advanced natural language processing. In 2013, word2vec introduced efficient methods for learning distributed word representations. In 2014–2015, sequence-to-sequence and attention mechanisms advanced neural machine translation. Deep learning's success led to an enormous increase in interest and funding in AI. The amount of machine learning research (measured by total publications) increased by 50% in the years 2015–2019.
== Impact == Martin Müller and Alexander Preker, writing for Der Spiegel in January 2024, have referred to Knudsen discovery in inventing the semaglutide weight-loss injections as "revolutionary", with the "drug Wegovy... [having] changed the world", and having "made Novo Nordisk Europe's most valuable company, with a greater market capitalization than Daimler, Bayer, Lufthansa and BMW combined." In the initial clinical trials for Wegovy, diabetics lost more than 10% of their weight and in trials for weight loss, patients lost an average of 12.4% of their weight. Additional patient benefits included reduction of cardiovascular events by 26%, and benefits to patients with heart and kidney failure. The GLP receptor agonists have reformed treatment outcomes for obesity and diabetes "with profound implications for maintaining human health."
== Somatostatin receptor agonists versus antagonists in radiolabelling == Agonists of the somatostatin receptor had been long established as an imaging agent, with the first agonist Ga-DOTATOC coming out in 2001, which is based on a radiolabeled somatostatin receptor agonist drug octreotide, and further developments were based on its structure. Agonists share the characteristic of being uptaken into tumor cells, and degraded intracellularly. Antagonists, while not widely absorbed into the tumor cells, can bind to a wider range of receptors as they can bind to the receptors regardless if the receptors are activated or inactivated. They thus are more sensitive to neuroendocrine tumors. Another study noted the antagonists showed lowered internalization into tumors, cleared from the blood quickly, and had a higher binding to tumors, which were noted to be properties benefitting its use over agonists in detecting metastatic tumors. A head-to-head study of the gallium-containing compounds, where the Ga-NODAGA-JR11 antagonist and Ga-DOTATOC agonist are directly compared, showed that Ga-NODAGA-JR11 had higher hepatic metastatic tumor detection rate and lesion sensitivity than Ga-DOTATOC. Another head-to-head study of lutetium containing compound found the antagonist Lu-DOTA-JR11 bound with the receptors more quickly, had a longer retention time and unbound more slowly than the Lu-DOTA-TATE agonist.
Sources: en.wikipedia.org
The amino acid sequence matches human growth hormone-releasing hormone, but the amino terminus carries a trans-3-hexenoyl group instead of a free amine. That single structural change chiefly affects enzymatic stability rather than receptor selectivity.
Growth hormone released from the pituitary stimulates IGF-1 production in the liver and other tissues, so circulating IGF-1 generally rises during exposure. The size of the rise varies between individuals and depends on baseline hormonal status and other concurrent factors.
Reported imaging studies focus on visceral adipose tissue, where reductions are more consistently observed across trials. Subcutaneous depots show smaller and less reproducible changes, so the two compartments should not be treated as equivalent.
It mimics a natural hypothalamic signal that tells the pituitary to release growth hormone. The result is a rise in circulating growth hormone and, indirectly, in insulin-like growth factor 1. Over weeks of treatment this shift is associated with a selective decrease in fat stored inside the abdomen.